CATALIS Québec is a non-profit organization whose governance relies on a network of public and private partners to carry out its mission and vision of operational improvement and excellence in clinical research in Quebec. The Advisory Committee plays an advisory role by supporting the executive management team in implementing the strategic plan and any priority actions approved by the board of directors.

Board of Directors

Marc Rivière

Marc Rivière MD

General Partner & CMO,
TVM Capital Life Sciences

Jean Groleau

Me Jean Groleau

Lawyer and co-founder Groleau Gauthier Plante LLP

Monique Lacroix

Country Head, Global Development Operations / Trial Monitoring
Novartis Pharmaceuticals Canada Inc.

Louise Proulx PhD, ICD.D

Corporate Director

Diane Gosselin PhD, MBA, ASC

President & CEO

Dr Wilson Miller

Wilson Miller MD

Co-Director of Clinical Research, Lady Davis Institute
Director, Clinical Research Unit, Jewish General Hospital
Director, Developmental Therapy, Department of Oncology, McGill University
James McGill Professor, Departments of Medicine and Oncology, McGill University

Dr Guy Rouleau

Guy A. Rouleau OC, OQ, MD, PhD, FRCPC, FRSC

Director of The Neuro (Montreal Neurological Hospital Institute)
Director of the Department of Neurology and Neurosurgery at McGill University
Director of the Department of Neuroscience at the McGill University Health Centre
Co-founder of the Tanenbaum Open Science Institute

Jefferson Tea PhD, MBA

Vice-President, Medical & Scientific Affairs
Takeda Canada Inc.

Observer Members

Martin Doyon ing. PhD

Director, Networking and Industrial Partner Direction
Ministry of the Economy and Innovation of Quebec

Julie Couture

Director of Data Quality, Research and Internal Coordination
Minister of Health and Social Services (MSSS)

Nathalie Girarding. PhD

Strategic Projects Coordinator, Life Sciences Branch
Ministère de l’Économie et de l’Innovation


François Painchaud

Corporate Secretary

Paul Lohnes

Treasurer, Director of Finance and Administration and Assistant Corporate Secretary

Operations Committee

Cinzia Raponi CPA, CMA

Director, Administration
Research Institute McGill University Health Centre (MUHC)

Claudette Boily

Senior Manager – Acting Clinical Research

Sylvie Cossette CPA, CA

Associate Director of Research
CHU Sainte-Justine

Annie Morin PhD

Acting Assistant to the Scientific Director, Research Center

Stéphane Bolduc MD FRCSC

Deputy-Director of clinical research
CHU de Québec – Université Laval

Pascale Landry PhD

Senior Clinical Research Associate, Clinical Research, Global Medical Division
GSK Canada

Sebastien Tremblay

Director, Site Relationship Partner
Director, Clinic Center Relationship Partner

Marie-France Goyer

Therapeutic Area Leader, Merck

Linda Carpentier

Head of Country Trial Operations
Team Leader, Clinical Operations

David Senac Eng.

Project Manager, Interventional Studies
Hoffmann-La Roche Limited (Roche Canada)

Isabelle Voccia Ph.D

Therapeutic Area Specialist – Oncology and Immunology
Clinical Trial Portfolio Manager
Boehringer Ingelheim

Jean-François Leger M.Sc.

Site Partnership Manager, Sanofi Canada

Yvon Fréchette Chemist, M.Sc.

Innovation Advisor, Collaborative Research Direction
Ministry of the Economy and Innovation of Quebec

Jenny Kaeding Ph.D

Ethics Advisor, Research and Internal Coordination Division
Ministry of Health and Social Services

Danika Laberge

President and CEO

Scientific Advisory Committee

Dr. Angela Genge Chair

Neurologist and Director, Clinical Research Unit

Montreal Neurological Institute and Hospital

Dr. John Mitchell

Pediatric Endocrinologist

Research Institute of the McGill University Health Centre (RI-MUHC)

Dr. Rahima Jamal 

Hemato-oncologist and Director of the Unit for Innovative Therapies

University of Montreal Hospital Research Centre (CRCHUM)

Dr. Michael Sebag

Hematologist, Research Institute

McGill University Health Centre (RI-MUHC)

Dr. Maxime Chénard-Poirier

Hematologist and Oncologis

CHU de Québec-Université Laval Research Center

Dr. Jean-Claude Tardif


Montreal Heart Institute Research Center

Scientific Director, Montreal Health Innovations Coordinating Centre (MHICC)

Dr. Jean-Philippe Lafrance


Maisonneuve-Rosemont Hospital Research Centre

Associate Professor, Department of Pharmacology and Physiology Université de Montréal

Dr. Michel Duval

Head of the Hematology-Oncology Department and clinical researcher

CHU Sainte-Justine Research Center

Dr. Wilson H. Miller

Director, Clinical Research Unit

Jewish General Hospital, Lady Davis Institute for Medical Research

Dr. André Carpentier

Director of the Diabetes, Obesity and Cardiovascular Complications Research Axis

Centre for Research at the CHUS (CRCHUS) – Université de Sherbrooke

Patient Advisory Committee

Marie-Christine Beauchemin

Information and Support Coordinator

PROCURE – The Force Against Prostate Cancer

Marie-Hélène Bolduc

Vice President, Programs and Services

Muscular Dystrophy Canada

Claudine Cook

Executive Director

The ALS Society of Quebec

Marie-Claude Dufour

Director, Programs & Services and Government Relations

Multiple Sclerosis Society of Canada

Sylvie Lauzon

President and CEO

Diabetes Québec

Francine Forget Marin

Director, Health promotion and Research

The Heart & Stroke Foundation

Gail Ouellette


Regroupement Québécois des Maladies Orphelines

Jessy Ranger

Director, Patient Programs, Health Policy & Advocacy

Myeloma Canada

Barry Stein


Colorectal Cancer Canada

Eva Villalba

Executive Director

Quebec Cancer Coalition

John Wallenburg

Chief Scientific Officer

Cystic Fibrosis Canada

Olivier Jerôme

Director, public and patient engagement


Cédric Baudinet

Project Manager, Investments and Health Promotion
Quebec Breast Cancer Foundation

Chantal Gobeil

Ataxia Charlevoix-Saguenay Foundation

François Laviolette *

Patient Partner

* François Laviolette was a true pillar of artificial intelligence research. In addition to his great passion and leadership in the field of data, he wished to give back by sharing his knowledge and vast experience until the last moment. Shortly before his passing, François had generously accepted to join the CATALIS-Clinical Research Quebec Patient Advisory Committee as the very first patient partner. In just a few months, François brought light and wisdom to the valorization of health research data and his work will continue to inspire our community. Our thoughts are with François’ family, colleagues and loved ones to whom we offer our deepest condolences.

Ethic Advisory Committee

Marie Hirtle LL.B., LL.M.,

President MUHC REB

Executive Assistant, DQEPE (Department of Quality, Evaluation, Performance and Ethics)

Me Brigitte Pâquet

Vice-President, REB MUHC

Assistant Director, Neuroethics Program

Me Marie-Josée Bernardi, Lawyer

President, Research Ethics Board

Head of the Office of Research Ethics

Annabelle Cumyn, MD, CM, MHPE

President, CIUSSS de l’Estrie-CHUS Research Ethics Board

Associate Professor, Department of Medicine, FMSS

Vanessa Chenel, PhD

Senior Ethics Advisor
President, Research Ethics Board
Department of Quality, Evaluation, Performance and Ethics

CIUSSS de l’Est-de-l’Île-de-Montréal

Me Geneviève Cardinal

President of the Research Ethics Committee

Head of the Research Ethics Office

Diane Major

President of the REB at the CHU de Québec

Éric Sévigny

PhD, Coordinator of the Research Ethics Board of the CISSS du Bas-Saint-Laurent

Management team

Danika Laberge PMP

President and CEO of CATALIS Québec

Ms. Laberge has over 25 years of professional experience in the research sector and the health and social services network. Drawing on her expertise, operational excellence-oriented approach, leadership, and management skills, she created a vast network of partners (“The CATALIS Network”), which she consults on an ongoing basis to identify issues within the province’s clinical research industry and develop effective communal solutions serving to accelerate the launch and optimize the conduct of clinical trials. Most notable of Ms. Laberge’s major accomplishments is the harmonization, with the participation of the CATALIS Network, of clinical research administrative practices, which led to the creation of the FAST TRACK evaluation service. This innovative program makes it possible to evaluate and authorize clinical trials in Quebec in less than eight weeks.
Before joining CATALIS, Ms. Laberge spearheaded numerous projects, including the launch of CARTaGENE, a Quebec biobank. She also oversaw the implementation and management of the McGill University Health Centre Research Institute’s McConnell Centre for Innovative Medical.

Paul Lohnes CPA, CA

Director Finance and Administration of CATALIS Québec

Paul Lohnes is a senior executive with over 40 years of experience in professional services organizations in Canada. His credentials include: audit and professional practice as a partner with KPMG in Montreal and The Netherlands; senior roles in audit standard-setting and audit regulation and quality control; and chief executive of a not-for-profit organization in the public sector. In addition to financial and audit acumen, he brings to CATALIS expertise in governance and human resources management. Paul has a keen interest in healthcare research and in contributing to achieving CATALIS’ mission. He is currently a member of the Board and the Audit and Infrastructure Committee of the Montréal West Island Integrated University Health and Social Services Centre, a member of the executive committee of the Interdisciplinary Canadian Collaborative Myalgic Encephalomyelitis Research Network (ICanCME), and a member of the Board of NOVA Hudson.

Olivier Jérôme

Director, public and patient engagement of CATALIS Québec

With over ten years of professional experience in the general and operational management of health organizations, Olivier Jérôme has overseen various mandates that focused on patients and their family caregivers. A seasoned administrator in the organizational development and operationalization of health programs, he has actively participated in creating, reorganizing, and expanding the units he was responsible for, including those in reproductive medicine, obstetrics, oncology, and rare diseases. Olivier also has a comprehensive understanding of the political environment and governmental affairs in health at the federal and provincial levels. He will use this expertise to benefit patients and family caregivers by facilitating and accelerating access to innovative health treatments. He joins the CATALIS team with a passion for both research and access to innovation in health care and will undoubtedly contribute to the success of its mission.

Maria Fraraccio

Project Manager – CATALIS Québec

With more than fifteen years of experience in internationally renowned Quebec institutes and research centers, Maria has led numerous phase II to IV clinical trials in various therapeutic fields and has extensive operational expertise more specifically in the processes related to feasibility, budget development and negotiation, and submissions for the triple review, namely science, ethics and institutional conformity. Supported by extensive knowledge of ICH GCP guidelines, Health Canada regulations and ministerial standards, she specializes in the development and support of clinical research activities, as well as coordination with the various key players to achieve clinical research targets and maximum performance.

As Project Manager, Maria will be responsible for the implementation of the new FAST TRACK review service. She will have the pleasure of working and supporting a network of committed and dedicated members who are all devoted to optimizing and accelerating the accessibility of clinical trials in Quebec.

profil Isabelle Sokolnicka

Isabelle Sokolnicka

Head of Communications – CATALIS Québec

Isabelle began her career as a science journalist, a role that allowed her to cover topics such as neurodevelopmental disorders affecting Canadian children and stem cell transplants for the treatment of cancer. A quadrilingual communications professional specialized in digital marketing, she is passionate about health and innovation; she was the project manager of the award-winning injury prevention program at the McGill University Health Centre. Isabelle has led national and international marketing communications initiatives in Canada and abroad in areas ranging from healthcare reform to the reduction of maternal and neonatal mortality, namely in collaboration with the University of Montreal Hospital Centre.

A brand builder and a seasoned strategist, Isabelle looks forward to joining the CATALIS team to elevate the organization’s profile and promote Quebec’s expertise in clinical research, and ultimately participate in the acceleration of innovative treatments.

Maryse Patenaude

Maryse Patenaude

Patient and Clinician Support Service Coordinator – CATALIS Quebec

Maryse Patenaude holds a Master of Genetic Counseling from the Université de Montréal and a Specialized Studies Diploma in Management from HEC Montreal. She has been working in the health field for almost twenty years. Having acquired experience in clinical research with the Breast Cancer Research Group (Groupe de recherche en cancer du sein), Maryse then worked as a genetic counselor for over 10 years. She was able to share her knowledge of medical genetics with many patients and health professionals, mainly in the fields of prenatal genetics, reproduction, and oncology. Maryse then participated in the coordination and management of a research unit in the field of medical data analysis and integration, while ensuring the utmost respect for patient confidentiality, as well as for current standards and regulations.

Having developed an empathetic, patient-oriented approach, and with her vast experience in the Quebec health sector, Maryse is enthusiastically joining the CATALIS team to participate in the development of the personalized clinical trial support service.

Alexandra Verreault

Alexandra Verreault

Project Manager – CATALIS Quebec

Alexandra brings close to 10 years of experience in the field of clinical research. During that time, she has led several Phase I to IV clinical trials, both industry and investigator initiated. Having overseen the continuous ethics review for the Office of Responsible Conduct in Research at the Université de Montréal and having been a member of the CHU Sainte-Justine Research Ethics Board, she has built up an expertise in the fields of research ethics and the regulatory environment of clinical research in Quebec. This knowledge was put into use and refined when she coordinated all clinical research, at the macro level, of a hospitalization unit at the CHU Sainte-Justine.

As Project Manager at CATALIS, Alexandra will be responsible, in collaboration with the other project managers, for the implementation of the new FASTTRACK evaluation service. She will have the pleasure of working with and supporting a network of committed and dedicated members who are all eager to optimize and accelerate the accessibility of clinical trials in Quebec.

Natalie Saunders

Natalie Saunders

Project Manager – CATALIS Quebec

Natalie holds a BSc in Neuroscience and a MSc in Occupational Therapy, both from McGill University. Upon completing her Master’s degree she worked as a clinical research coordinator for several international phase 1-3 ALS studies at the Montreal Neurological Institute and Hospital, a top enrolling site. Natalie has extensive knowledge in neuromuscular diseases, good clinical practice, and clinical outcome measures. Before joining CATALIS, Natalie mentored a team of clinical research coordinators in ALS, overseeing approximately 15 trials at a time, while also partaking in start-up activities for new ALS studies.

Passionate about patient care and education, Natalie has participated in ALS support groups, educated newly diagnosed patients about clinical research, and contributed to clinical management research studies. She has attended and presented at national and international conferences for ALS, networking with researchers and sponsors around the world.As a Project Manager, Natalie will partake in the FAST TRACK program with the goal of helping patients obtain better access to clinical trials in Quebec.